Table 2.

Association of candidate protein markers with response and development of irAEs after pembrolizumab treatmenta

Group A (n = 6)Group B (n = 6)Group C (n = 8)Group D (n = 4)
No responseNo response+response+ response
ProteinNo toxicity+ toxicity+ toxicityNo toxicity
PD-1Increased in 2 patientsIncreased in 5 patientsIncreased in 4 patientsIncreased in 2 patients
TSHBDecreased in 3 patientsDecreased in 3 patients
Increased in 1 patient
NT-proBNPIncreased in 1 patientDecreased in 2 patientsDecreased in 1 patient
Increased in 1 patient
CASP-3Increased in 2 patients
Il-17CDecreased in 2 patientsIncreased in 1 patient
PMVKIncreased in 2 patientsDecreased in 1 patientIncreased in 1 patient
Decreased in 1 patient
PTPN1Increased in 2 patientsDecreased in 1 patient
FKBP5Increased in 2 patientsDecreased in 1 patient
Decreased in 1 patient
  • aIncreased or decreased is defined as a 4-fold or higher concentration change in the post treatment sample, as compared with the pretreatment sample. For more details see text.